COMPANY PROFILE

Regor Therapeutics

Explore full profile

Innovative drug candidates targeting metabolism, oncology, and autoimmunity with potential blockbuster therapies

Xuhui District, ChinaFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Regor Therapeutics

Regor Therapeutics Group focuses on developing innovative drug candidates to address significant unmet medical needs in the fields of metabolism, oncology, and autoimmunity. The company operates in the biopharmaceutical sector, leveraging its Computer Accelerated Rational Discovery platform to expedite the drug discovery process. Regor's clinical pipeline includes promising candidates such as RGT-075, a once-daily oral small molecule full agonist of GLP-1R, and RGT-419B, a next-generation CDK4 inhibitor showing efficacy in refractory ER HER2 breast cancer. The company collaborates with global leaders like Lilly to enhance its research and development capabilities. Regor primarily serves patients with metabolic disorders, various cancers, and autoimmune diseases, aiming to bring breakthrough therapies to market. The business model revolves around research and development, clinical trials, and strategic partnerships, generating revenue through licensing agreements and potential future drug sales.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Xuhui District, China
Employees: 38
Open positions: 1
Dealroom signal: 85.6/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Dec 2021	$50M	$200M	Eli Lilly	↗
SERIES BOther financing	Feb 2021	$90M	$360M	Vertex Holdings · TF Capital · Lanting Capital · Loyal Valley Capital	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Regor Therapeutics website traffic

Latest recorded traffic for Regor Therapeutics is 4K monthly website visits, up 135.3% over the last three months. Regor Therapeutics's team grew 8.6% over the past year.

Latest monthly visits4K 3-month web change+135.3% 1-year team growth+8.6%

Monthly website visitsOct 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
NONovaceaBiotech & Life Sciences	San Francisco, United States	Acquired
PUPulmobioticsDiscovers and develops novel treatments and vaccines for respiratory diseases	Barcelona, Spain	Operational
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational